- 全球顶尖药企对歌礼已进入临床阶段的多个候选药物表达了浓厚兴趣,将与歌礼洽谈潜在的授权引进(in-licensing from Ascletis)。- 歌礼将与超35家企业会面洽谈,其中包括全球前15大制药巨头中的七成企业。香港,2025年6月15日--歌礼制药有限公司(香港联交所代码:1672,“歌礼”)宣布歌礼创始人、董事会主席兼首席执行官吴劲梓博士和首席商务官John P. ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.